Innervace

Philadelphia, United States

Innvervace develops regenerative therapy solutions for neurodegenerative disorders.

$40.0M raised

Sep 2022

Series A

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Innervace raised?

Innervace has raised $40.0M in total funding. The most recent round was Series A. The last funding was announced in September 2022.

Who are Innervace's investors?

Innervace's investors include BioAdvance, Deerfield, IP Group, WARF Ventures, Penn Medicine Co-Investment Program.

Where is Innervace headquartered?

Innervace is headquartered in Philadelphia, United States.

What does Innervace do?

Innvervace develops regenerative therapy solutions for neurodegenerative disorders.

What stage is Innervace at?

Innervace is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated September 8, 2022.

MLA

"Innervace — Funding & Investors." VCBacked, September 8, 2022, https://www.vcbacked.co/company/innervace. Accessed July 2, 2026.

APA

VCBacked. (2022). Innervace — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/innervace

Wikipedia (cite web)

{{cite web |title=Innervace — Funding & Investors |url=https://www.vcbacked.co/company/innervace |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated September 8, 2022.